Group 1 - The core viewpoint of the article is that卓正医疗 has passed the main board listing hearing and is focusing on the mid-to-high-end medical service market in China, targeting affluent customers [1] -卓正医疗 aims to become the third largest private mid-to-high-end comprehensive medical service provider in China by 2024, with a market share of 2% in this segment and approximately 0.1% in the broader mid-to-high-end market [1] - The private mid-to-high-end medical service market in China is projected to grow at a compound annual growth rate (CAGR) of 21.9% from 2020 to 2024, and is expected to continue growing at a CAGR of 14.3% from 2024 to 2029 [1] Group 2 -卓正医疗 has established a network of medical service institutions in several developed cities in China, with plans to operate 19 facilities by October 28, 2025, and has clinics in Singapore and Malaysia [1]
卓正医疗通过港交所聆讯，专注服务中高端医疗服务市场
Cai Jing Wang·2025-12-17 03:43